UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended                         Commission File No.
   June 30, 1997                                  0-15443

  THERAGENICS CORPORATION
       (Exact name of registrant as specified in its charter)


        Delaware                           58-1528626
(State of incorporation)      (I.R.S. Employer Identification Number)



       5325 Oakbrook Parkway
        Norcross, Georgia                                 30093
(Address of principal executive offices)               (Zip Code)



Registrant's telephone number, including area code: (770) 381-8338

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such  reports), and (2) has been subject to such filing
requirements  for the past 90 days.  YES    X      NO

As of August 11,  1997 the  aggregate  market  value of the common  stock of the
registrant held by  non-affiliates  of the registrant as determined by reference
to the closing price of Common Stock as reported on the Nasdaq  National  Market
System, was $399,806,904.  As of August 11, 1997 the number of shares of common
stock, $.01 par value, outstanding was 14,407,456.


<PAGE>







                             THERAGENICS CORPORATION

                                TABLE OF CONTENTS



PART I  - FINANCIAL INFORMATION:

         ITEM 1.  FINANCIAL STATEMENTS                                  Page No.

               Balance Sheets - December 31, 1996 and June 30, 1997
              (unaudited)...........................................       3

               Statements of Earnings for the Three Months and Six 
               Months Ended June 30, 1996 and 1997 (unaudited)......       5

               Statements of Cash Flows for the Three Months and Six
               Months Ended June 30, 1996 and 1997 (unaudited)......       6

               Statements of Changes in Stockholders' Equity for the
               Three Months and Six Months Ended June 30, 1997
               (unaudited)..........................................       7

               Notes to Financial Statements........................       9


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS..................................      11

PART II - OTHER INFORMATION

      ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.....................      15

SIGNATURE...........................................................      16


<PAGE>
<TABLE>


                         PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements
          --------------------

                                           THERAGENICS CORPORATION

                                                BALANCE SHEETS

                                      DECEMBER 31, 1996 AND June 30, 1997

                                                     ASSETS
<CAPTION>

                                                          December 31,                June 30,
                                                             1996                       1997
                                                         ------------             ------------
                                                                                  (Unaudited)
<S>                                                      <C>                      <C>                                   
CURRENT ASSETS
   Cash and short-term investments                       $  2,986,123             $ 36,342,099
   Trade accounts receivable                                2,258,936                4,384,588
   Inventories                                                229,298                  413,228
  Prepaid expenses and other current assets                   133,625                  195,433
      TOTAL CURRENT ASSETS                               ------------             ------------
                                                            5,607,982               41,335,348

PROPERTY AND EQUIPMENT
   Building                                                 3,333,728                3,333,728
   Leasehold improvement                                      138,978                  138,978
   Machinery and equipment                                 11,522,064               14,614,660
   Office furniture and equipment                              65,057                   69,057
                                                         ------------             ------------
                                                           15,059,827               18,156,423
   Less accumulated depreciation
     and amortization                                      (3,237,684)             ( 4,007,183)
                                                         ------------             ------------
                                                           11,822,143               14,149,240
                                                         ------------             ------------
  Land                                                        525,372                  525,372
  Construction in progress                                  5,238,056                6,604,662
                                                         ------------             ------------
       TOTAL PROPERTY & EQUIPMENT                          17,585,571               21,279,274

OTHER ASSETS
  Deferred tax asset                                          360,000                       --
  Patent Costs
  Patent costs                                                 80,685                   76,260
  Other                                                        55,183                    6,424
                                                         ------------             ------------
       TOTAL OTHER ASSETS                                     495,868                   82,684
                                                         ------------             ------------
          TOTAL ASSETS                                   $ 23,689,421             $ 62,697,306
                                                         ============             ============
</TABLE>

<PAGE>

<TABLE>
<CAPTION>


                                                   THERAGENICS CORPORATION

                                                         BALANCE SHEETS
                                                           (Continued)

                                                DECEMBER 31, 1996 AND JUNE 30, 1997

                                               LIABILITIES AND STOCKHOLDERS' EQUITY

                                                          December 31,               June 30,
                                                            1996                       1997
                                                        --------------           --------------
                                                                                   (Unaudited)
<S>                                                     <C>                      <C>
CURRENT LIABILITIES:
   Current portion of long term debt                    $  3,458,436             $         --
Trade accounts payable
  Trade accounts payable                                     330,375                  772,895
   Accrued salaries, wages, and payroll taxes                459,421                  386,319
   Income taxes payable                                           --                  732,126
   Other current liabilities                                  56,677                  229,779
                                                        ------------             ------------
   TOTAL CURRENT LIABILITIES                               4,304,909                2,121,119


DEFERRED INCOME TAX                                               --                  535,000

STOCKHOLDERS' EQUITY:
  Common stock, $.01 par value,
  50,000,000 shares authorized;  11,814,278
  and 14,399,456 shares had been issued
  as of December 31, 1996 and June 30, 1997,
  respectively.                                              118,143                  143,994
  Additional paid-in capital                              17,616,560               54,956,058
  Retained earnings                                        1,649,809                4,941,135
                                                        ------------             ------------
    TOTAL STOCKHOLDERS' EQUITY                            19,384,512               60,041,187
                                                        ------------             ------------
      TOTAL LIABILITIES/STOCKHOLDERS' EQUITY            $ 23,689,421             $ 62,697,306
                                                        ============             ============
</TABLE>


The  accompanying  notes are an  integral  part of these statements.


<PAGE>
<TABLE>
<CAPTION>



                                                                     THERAGENICS CORPORATION

                                                                      STATEMENTS OF EARNINGS
                                                  FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 1996 AND 1997
                                                                             (Unaudited)

                                                   Three Months                                       Six Months
                                                   Ended June 30                                     Ended June 30
                                       -------------------------------------            -------------------------------------
                                            1996                    1997                     1996                    1997
                                       -------------           -------------            -------------           -------------
<S>                                    <C>                     <C>                      <C>                     <C>

REVENUES:
Sales..........................        $  2,726,535            $  6,147,499             $  5,423,569            $ 10,229,857
Licensing fee..................                 --                   25,000                  101,322                  50,000
                                        -----------             -----------              -----------             -----------
                                          2,726,535               6,172,499                5,524,891              10,279,857
COSTS & EXPENSES:
   Cost of sales...............             886,988               1,559,340                1,640,611               2,704,701
   Selling, general and
     administrative............             770,828               1,390,978                1,463,600               2,576,106
   Research and development                   1,085                  30,112                    2,174                  34,477
                                        -----------             -----------              -----------             -----------
                                          1,658,901               2,980,430                3,106,385               5,315,284
OTHER INCOME (EXPENSE):
   Interest income.............              34,262                 381,488                   72,157                 394,719
   Interest expense............             ( 9,580)                ( 7,992)                 (12,669)                (14,621)
   Other.......................                 908                 (45,676)                 ( 7,065)                (36,081)
                                        -----------             -----------              -----------             -----------
                                             25,590                 327,820                   52,423                 344,017
NET EARNINGS BEFORE
 INCOME TAXES..................        $  1,093,224            $  3,519,889                2,470,929               5,308,590
Income tax expense.............             415,425               1,337,558                  938,953               2,017,264
                                        -----------             -----------              -----------             -----------
NET EARNINGS...................        $    677,799            $  2,182,331             $  1,531,976            $  3,291,326
                                        ===========             ===========              ===========             ===========
NET EARNINGS PER COMMON SHARE
(Note B).......................        $        .06            $        .15             $        .13            $        .24
                                        ===========             ===========              ===========             ===========
WEIGHTED AVERAGE SHARES                  12,203,945              14,762,729               12,170,261              13,586,435
                                        ===========             ===========              ===========             ===========
</TABLE>

The accompanying notes are an integral part of these statements.



<PAGE>
<TABLE>
<CAPTION>


                                                                    THERAGENICS CORPORATION
                                                                    STATEMENTS OF CASH FLOWS
                                               FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 1996 AND 1997
                                                                          (Unaudited)

                                                                     Three Months                            Six Months
                                                                     Ended June 30                          Ended June 30

                                                            1996                 1997                 1996                1997
                                                      ----------------    ----------------     ----------------    ----------------
<S>                                                   <C>                  <C>                 <C>                  <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
 Net earnings.......................................  $    677,799         $  2,182,332        $   1,531,976        $   3,291,326
 Adjustments to reconcile net earnings
 to net cash provided by operating
 activities:
   Depreciation and amortization....................       227,053              425,478              444,618              773,924
   Changes in assets and liabilities:
   Accounts receivable..............................       107,987           (1,639,921)            (397,415)          (2,125,652)
   Inventories......................................     (  39,085)          (  100,435)            (    692)          (  183,930)
   Prepaid expenses and other current assets........        63,443                4,687             ( 42,179)          (   61,808)
   Deferred tax asset...............................     (  93,443)                  --              426,067              360,000
   Other assets.....................................           538                   --             (  3,729)                  --
   Trade accounts payable...........................       310,038              179,961              356,460              442,520
   Accrued salaries, wages and payroll taxes........        89,574              223,369                4,960           (   73,102)
   Income taxes payable.............................            --              662,558                   --              732,126
   Other current liabilities........................        11,090               59,021               24,653              173,102
   Deferred tax liability...........................            --              535,000                   --              535,000
                                                        ----------           ----------           ----------           ----------
     Total Adjustments                                     677,195              349,718              812,743              572,180
                                                        ----------           ----------           ----------           ----------
        Net cash provided by
        operating activities........................     1,354,994            2,532,050            2,344,719            3,863,506

CASH FLOWS FROM INVESTING ACTIVITIES:
   Purchases and construction of property
     and equipment..................................    (1,912,690)          (1,077,414)          (3,716,749)          (4,463,202)
                                                        ----------           ----------           ----------           ----------
        Net cash used by investing
        activities..................................    (1,912,690)          (1,077,414)          (3,716,749)          (4,463,202)
</TABLE>

<PAGE>
<TABLE>
<S>                                                      <C>                 <C>                  <C>                  <C>

CASH FLOWS FROM FINANCING ACTIVITIES:
  Repayment of term loan ...........................     ( 126,246)                  --           (  250,205)                  --
  Net borrowing (repayment) of revolving line
    of credit.......................................            --           (5,626,267)                  --           (3,458,436)
  Exercise of stock options and warrants (net)......       669,290                1,500              844,389              348,051
  Secondary Stock Offering (net)....................            --           32,155,201                   --           32,017,298
  Stock purchased for Marketing & Sales Agreement               --            5,000,000                   --            5,000,000
    with Indigo Medical, Inc.(Johnson & Johnson 
    Development Corp.)..............................
  Debt issue costs..................................            --               50,889                   --               48,759
                                                        ----------           ----------           ----------           ----------
        Net cash (used) provided by
        financing activities........................       543,044           31,581,323              594,184           33,955,672

NET INCREASE (DECREASE) IN CASH AND
  SHORT-TERM INVESTMENTS............................     (  14,652)          33,035,959           (  777,846)          33,355,976
CASH AND SHORT-TERM INVESTMENTS AT
  BEGINNING OF PERIOD...............................     2,503,144            3,306,140            3,266,338            2,986,123
                                                        ----------           ----------           ----------           ----------
CASH AND SHORT-TERM INVESTMENTS AT
  END OF PERIOD.....................................   $ 2,488,492         $ 36,342,099         $  2,488,492         $ 36,342,099
                                                        ==========           ==========           ==========           ==========
</TABLE>

The  accompanying  notes are an integral part of these statements.


<PAGE>
<TABLE>


                                                                     THERAGENICS CORPORATION

                                                         STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
                                                             FOR THE SIX MONTHS ENDED JUNE 30, 1997
                                                                           (Unaudited)


                                                  Common Stock
                                            -------------------------      Additional
                                            Number of       Par Value        Paid-in         Retained
                                             shares           $.01           Capital         Earnings          Total
                                           ------------   ------------    -------------   -------------    -------------
<S>                                         <C>           <C>             <C>              <C>             <C>

BALANCE, December 31, 1996........          11,814,278    $   118,143     $ 17,616,560     $ 1,649,809     $ 19,384,512
 Exercise of stock options........              30,725            307           97,605                           97,912
 Secondary Stock Offering (net)...           2,300,000         23,000       31,994,298                       32,017,298
 Johnson & Johnson Development
   Corp. stock purchase...........             254,453          2,544        4,997,456                        5,000,000
 Income tax benefit from stock
  options exercised...............                                             250,139                          250,139
 Net earnings for the period......                                                           3,291,326        3,291,326

BALANCE, June 30, 1997............          14,399,456    $   143,994      $54,956,058     $ 4,941,135     $ 60,041,187

</TABLE>

The accompanying notes are an integral part of these statements.


<PAGE>



                             THERAGENICS CORPORATION


                          NOTES TO FINANCIAL STATEMENTS
                                  JUNE 30, 1997
                                   (Unaudited)



NOTE A - BASIS OF PRESENTATION

The interim  financial  statements  included  herein  have been  prepared by the
Company without audit.  These statements  reflect all adjustments  which are, in
the opinion of management, necessary to present fairly the financial position as
of June 30,  1997,  and the results of  operations,  cash flows,  and changes in
shareholders  equity for the three and six months ended June 30, 1997.  All such
adjustments are of a normal recurring nature.  Certain  information and footnote
disclosures  normally  included in financial  statements  prepared in accordance
with generally  accepted  accounting  principles have been condensed or omitted.
The Company  believes that the  disclosures are adequate to make the information
presented not misleading.  It is suggested that these  financial  statements and
notes be read in conjunction with the audited financial statements and notes for
the year  ended  December  31,  1996,  included  in the Form  10-K  filed by the
Company.

NOTE B - NEW ACCOUNTING PRONOUNCEMENT

The  FASB  (Financial  Accounting  Standards  Board)  has  issued  Statement  of
Financial  Accounting  Standards No. 128, Earnings Per Share, which is effective
for financial  statements  issued after December 15, 1997. Early adoption of the
new standard is not  permitted.  The new standard  eliminates  primary and fully
diluted  earnings  per  share and  requires  presentation  of basic and  diluted
earnings per share  together  with  disclosure of how the per share amounts were
computed.  The  adoption of this new standard is not expected to have a material
impact on the disclosure of earnings per share in the financial statements.

NOTE C - HEDGING ACTIVITIES

The Company enters into foreign  exchange  forward  contracts to hedge the price
risks  associated  with equipment  purchase  commitments  denominated in foreign
currencies.  These contracts  reduce currency risk from exchange rate movements.
The  company  does not hold  foreign  exchange  forward  contracts  for  trading
purposes.  Gains  and  losses  are  deferred  and  accounted  for as part of the
underlying  transaction.  Deferred gains and losses were not significant at June
30, 1997.

<PAGE>

NOTE D - AGREEMENT WITH INDIGO MEDICAL, INC.

On May 30, 1997,  the Company  reached an agreement  with Indigo  Medical,  Inc.
(Indigo),  a  subsidiary  of Johnson & Johnson,  granting  Indigo the  exclusive
worldwide  right to market and sell  Theraseed(R)  for the treatment of prostate
cancer for a period of seven years with a provision  for  successive  three year
renewals.  Commencing with this transition,  all Theraseed(R)  products used for
the treatment of prostate cancer will be sold to Indigo.



<PAGE>


Item 2. - Management's Discussion and Analysis of
          ---------------------------------------
          Financial Condition and Results of Operations
          ---------------------------------------------

Results of Operations

Revenues - Revenues for the quarter were up 126% over the second quarter of 1997
contributing to Y-T-D revenues ($10,279,857) being 86% higher than the first six
months of last year. As in the first  quarter of this year,  the increase can be
primarily attributed to an increase in the number of TheraSeed(R) procedures
being performed for the treatment of prostate cancer.  Second quarter revenues
also increased as a result of a twenty-one  percent price  increase per seed in
May of 1997. Manufacturing continued to provide a consistent flow of product to
make the sales gains possible.

The Company's  net profit  improved  222% to  $2,182,331  or $.15 per share in
the second quarter of 1997, from $677,799 or $.06 per share for the same period
in 1996. Y-T-D profits grew 115% to $3,291,326 from $1,531,976 with earnings per
share of $.24 versus $.13.

On May 30, 1997,  the Company  reached an agreement  with Indigo Medical Inc., a
Johnson & Johnson  subsidiary,  granting Indigo the exclusive worldwide right to
market and sell TheraSeed(R) for the treatment of prostate cancer. Management
believes  that  as  a  result  of  this  agreement;  i)future  margins  will  be
temporarily depressed because the Theraseed(R)  transfer price to Indigo will
be less than the $38 per seed  price for  Theraseed(R)  charged  prior to the
recent price increase, ii)as production capacity is added Indigo will be able to
increase sales beyond that which  Theragenics  could accomplish on its own, iii)
Theragenics  will be able to avoid  making the large  investment  in  building a
sales, training and marketing  organization necessary if Theragenics were to try
to  continue  to  market  Theraseed(R)  independently  and  iv)ultimately  by
leveraging  Johnson & Johnson's  marketing  muscle and  international  presence,
Theragenics  will be able to generate  higher  sales and  profits  than it could
independently.  Transition  of sales  and  marketing  responsibility  to  Indigo
occurred in July at which time  Theragenics  began selling  Theraseed(R)  for
prostate cancer to Indigo and Indigo in turn began selling to the end user.

Cost and Expenses - Cost of sales for the second  quarter of 1997 increased over
the second quarter of 1996 by $672,332  primarily due to costs  associated  with
the 126% increase in sales. Year to date 1997 cost of sales increased almost 65%
or  $1,064,090  over the same period last year  reflecting  the 86%  increase in
sales for the same period and the increase in the Company's fixed cost base as a
cyclotron was added in the first quarter.

<PAGE>

S,G&A  expenses for the second  quarter of 1997  increased  80% or $620,150 over
S,G&A  expenses for the second  quarter of 1996. As the number of employees grew
to  support  overall  increases  in the scope of the  Company's  operations  and
efforts to attract and retain qualified employees continued, compensation levels
and related  expenses  increased.  These  expenses  accounted for an increase of
approximately  $219,000  for the  second  quarter of 1997  compared  to the same
period in 1996 and a $431,000  increase for 1997 Y-T-D  versus 1996 Y-T-D.  As a
result of negotiations  on the sales and marketing  agreement with the Johnson &
Johnson  subsidiary,  Indigo Medical,  Inc., legal and other  professional  fees
increased by approximately $259,000 in the second quarter 1997 versus 1996 while
1997 Y-T-D  spending  increased  $412,000 over 1996 Y-T-D.  Due to the nature of
these  expenses,  however,  these  charges  will be  non-recurring.  In a direct
relationship  to the  increasing  number  of  shareholders  eligible  to vote at
Theragenics'  annual  meeting,  costs for annual  meeting  materials and mailing
increased by $69,000 for second quarter 1997 over second quarter 1996. Insurance
premiums and property  taxes  increased by $32,000 in second quarter 1997 versus
second  quarter 1996 and $65,000 for 1997 Y-T-D over 1996 Y-T-D  reflecting  the
higher asset values of the Company to be insured and taxed. Other S,G&A expenses
increased  a net of  approximately  $40,000 for 1997  second  quarter  over 1996
second  quarter  and  $75,000  for 1997 Y-T-D over 1996 Y-T-D in response to the
volume increase of workload associated with increased sales.

Investments in research and development increased  approximately $32,000 in 1997
over the  same six month  period in 1996.  As the Company  grows,  the  Company
expects to continue to increase investments in research and development to
improve existing processes and explore other areas of opportunity.

Increases in other income and expense for the second quarter of 1997 and year to
date 1997 reflect interest received from short term investments.

Liquidity and Capital Resources

The Company had cash,  cash  equivalents  and  short-term  investments of $36.3
million  on June 30,  1997  compared  to $3.0 million  on  December  31,  1996.
Operations  generated  $3.9 million in cash. The following items contributed to
this increase. Net earnings accounted for $3.3 million supplemented by the 
utilization of the $360,000 deferred tax asset, the recognition  of a deferred 
tax liability of $535,000 and the accounting for the current income tax payable
at $732,126.  In  addition,  non-cash  depreciation expense was $773,924, trade
accounts  payable increased by $442,520 and other current liabilities increased
by $173,126.  This was primarily  offset by a $2 million increase in accounts 
receivable and small inventory and prepaid expense increases and payment of 
accrued salaries.

During  the first half of 1997,  the  Company  used $4.5  million  for  progress
payments on the Company's  current capacity  expansion  project.  This expansion
project,  which  management now estimates will cost  approximately  $22 million,
includes a manufacturing  facility and four cyclotrons.  Spending on the project
to date has been approximately $6.2 million.

Early in the second quarter the entire outstanding  amount,  $3.5 million,  from
Theragenics' credit facility was repaid effectively closing the credit facility.
Consequently, all remaining lump sum issue costs (approximately $51,000) related
to the credit  facility that were to be amortized over the life of the loan were
expensed in the second quarter.

Early in the  second  quarter,  the  Company  completed  a  underwritten  public
offering of 2,300,000  shares of common  stock  generating  approximately  $32.1
million in net proceeds to the Company after commissions and other expenses. The
Company has utilized and will  continue to utilize the proceeds for the capacity
expansion  project  mentioned  previously.  The Company has and will continue to
invest unused portions of the proceeds in short-term,  liquid,  investment grade
instruments,  certificates of deposit or direct or guaranteed obligations of the
United  States or its  agencies.  Exercise of options and warrants  generated an
additional $.3 million for the Company in the first six month of 1997.

In  connection  with  the  definitive  sales  and  marketing  agreement  between
Theragenics  and  Indigo,  Johnson  &  Johnson,  through  the  Johnson & Johnson
Development  Corporation,  also acquired  254,453 shares of  Theragenics  common
stock  through a  private  placement  for an  aggregate  purchase  price of $5.0
million.  The share price was  established  by averaging the average of the high
and low daily sales prices of Theragenics  common stock over the 20 trading days
prior to issuance.

Management believes existing cash and short-term investments together with funds
generated  from  operations  will be sufficient to meet the Company's  operating
requirements  through 1998. In the event additional financing becomes necessary,
management  may choose to raise those funds  through other forms of financing as
appropriate.

This document contains certain forward-looking  statements within the meaning of
the  Private  Securities  Litigation  Reform  Act  of  1995  including,  without
limitation,  statements regarding possible benefits associated with the alliance
with Indigo Medical Inc.,  future costs of sales,  S,G&A expenses,  research and
development,  costs of capacity  expansion and the  sufficiency of the Company's
liquidity and capital  resources.  From time to time,  the Company may also make
other forward-looking statements relating to such matters as well as anticipated
financial performance, business prospects, technological developments,  research
and development activities and similar matters. These forward-looking statements

<PAGE>

are subject to certain risks,  uncertainties and other factors which could cause
actual results to differ  materially  from those  anticipated,  including  risks
associated  with  the  management  of  growth,   government  regulation  of  the
therapeutic  radiological  pharmaceutical  and device  business,  dependence  on
health care professionals, and competition from conventional and newly developed
methods of treating localized cancer.

<PAGE>

PART II - OTHER INFORMATION

Item 2.- Changes in Securities

         On May 30, 1997,  the Company  issued  254,453  shares of common stock 
to Johnson & Johnson Development Corporation for proceeds of $5.0 million to the
Company in reliance upon the exemption from the registration requirements of the
Securities Act of 1933 provided by Section 4(2) thereof.

Item 4.- Submission of Matters to a Vote of Security Holders


         (a) The annual meeting of shareholders was held June 6, 1997;

         (b) Charles M. Klimkowski and Otis  W. Brawley, M.D. were reelected to 
             the board of directors and will each serve for a three-year term.  
             Mr. Klimkowski  received  11,132,885 votes for his election and 
             35,747 votes withheld authority. Dr. Brawley  received 11,132,815  
             votes for his election  and 35,817 votes withheld authority.

             The appointment of Grant Thornton as independent accountants for 
             the Company for the fiscal year ending December 31, 1997,  was 
             ratified and approved by a vote of 11,107,586 shares for and 26,475
             shares against, with 34,571 shares abstaining from voting.

             An  amendment to the Company's 1995 Stock Option Plan to limit
             individual annual awards thereunder was approved by a vote of
             10,766,717 shares for and 307,884 shares against, with 94,031
             shares abstaining.

             The Company's  1997 Stock Incentive Plan was approved by a vote of
             10,476,878 shares for and 590,781 shares against, with 100,973  
             shares abstaining.

Item 6.- Exhibits and Reports on Form 8-K


            (a)  Exhibit 27 - Financial Data Schedule

            (b)  Reports on Form 8-K.

                 No reports on Form 8-K were filed during the quarter ended   
                 June 30, 1997


<PAGE>



                                                      SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the  
undersigned  thereunto duly authorized.



                                            REGISTRANT:

                                  THERAGENICS CORPORATION


                                  By:  /s/ M. Christine Jacobs
                                  ----------------------------
                                       M. Christine Jacobs
                                       President



                                      /s/ Bruce W. Smith
                                  ----------------------------              
                                       Bruce W. Smith
                                       Treasurer and
                                       Chief Financial Officer


Dated: August 15, 1997